根据名称进行药物检索

Hemangeol与肝病

Hemangeol与肝病安全配伍检测的结果。

检测结果:

Hemangeol <> 肝病

现实性: 23.07.2019 评论家: 医学副博士Shkutko P.M., in

通过权威的信息来源 Drugs.com、Rxlist.com、Webmd.com、Medscape.com，在进行所选药物与这种伴发疾病互相作用检测时，发现一些会产生负面影响或对身体危害的禁忌症及副作用。

用户:

这种药物主要代谢通过的肝脏。肝病患者可以在更大的风险不利影响，这种药物由于减少药物清关。治疗与心得应给予谨慎的患者的肝脏疾病。量的调整可能是必要的。

来源

George CF, Orme ML, Buranapong P, et al "Contribution of the liver to overall elimination of propranolol." J Pharmacokinet Biopharm 4 (1976): 17-27
Silber BM, Holford NH, Riegelman S "Dose-dependent elimination of propranolol and its major metabolites in humans." J Pharm Sci 72 (1983): 725-32
"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Sotaniemi EA, Anttila M, Pelkonen RO, et al "Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity." Clin Pharmacol Ther 26 (1979): 153-61
Jones DB "Propranolol disposition in cirrhosis ." Gut 26 (1985): 865
Routledge PA, Shand DG "Clinical pharmacokinetics of propranolol." Clin Pharmacokinet 4 (1979): 73-90
Arthur MJ, Tanner AR, Patel C, et al "Pharmacology of propranolol in patients with cirrhosis and portal hypertension." Gut 26 (1985): 14-9
Pessayre D, Lebrec D, Descatoire V, et al "Mechanism for reduced drug clearance in patients with cirrhosis." Gastroenterology 74 (1978): 566-71
Walle T, Walle K, Mathur RS, Palesch YY, Conradi EC "Propranolol metabolism in normal subjects: association with sex steroid hormones." Clin Pharmacol Ther 56 (1994): 127-32
Branch RA, Shand DG "Propranolol disposition in chronic liver disease: a physiological approach." Clin Pharmacokinet 1 (1976): 264-79
Watson RG, Bastain W, Larkin KA, et al "A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls." Br J Clin Pharmacol 24 (1987): 527-35